In particular, the ability of PDE5i to interfere with the NO/cGMP/PKG/CREB signaling pathway by increasing the levels of cGMP has prompted the hypothesis that PDE5 inhibition might represent an effective therapeutic approach for the treatment of AD. The gene discussed is CREB1; the disease is Alzheimer disease.